已发表论文

预处理炎症生物标志物在原发性血管肉瘤中的预后价值

 

Authors Wang M, Wu S, Tong A, Cui X, Ma X

Received 12 June 2019

Accepted for publication 1 August 2019

Published 22 August 2019 Volume 2019:11 Pages 7981—7989

DOI https://doi.org/10.2147/CMAR.S219237

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 2

Editor who approved publication: Dr Chien-Feng Li

Background: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in patients with primary angiosarcoma (AS) which is a rare and highly malignant type of soft tissue sarcoma.
Methods: Fifty-six patients diagnosed with primary AS at West China Hospital between August 2009 and July 2016 were retrospectively enrolled. The value of each biomarker was calculated for its correlation with patients’ overall survival.
Results: The low tumor grade, tumor size <5 cm, metastatic status, surgical treatment and low level of monocyte-to-lymphocyte ratio, NLR and lactate dehydrogenase (LDH) were correlated with better survival outcome in univariate analyses. In multivariate analyses, high levels of NLR (HR 2.673, 95% CI 1.253–5.703, =0.011) and LDH (HR 2.964, 95% CI 1.464–5.998, =0.003) were selected as independent prognostic factors.
Conclusion: This study identifies the elevated pretreatment levels of NLR and LDH as prognostic markers in patients with primary AS.
Keywords: inflammatory biomarker, prognosis, angiosarcoma




Figure 1 ROC of NLR, PLR, MLR, SII, LDH and ALP for patients’ overall survival.